Breast cancer is the most commonly diagnosed cancer and is the second most common cause of cancer-related death among women in the US, leading to over 40,000 deaths annually.
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Eligibility for chemoprevention in the clinical trials included a 1.67 % 5-year risk of breast cancer or a 20 % lifetime risk. 9, 13, 14 It is estimated that 10 million, or 15.5 %, of US women aged 35-79 meet this high-risk threshold, however, fewer than 5 % of women who are offered chemoprevention agree to take it. 12, 15 Much has been written on this low uptake, however, it is primarily attributed to the risk for side effects and lack of knowledge about chemoprevention options among primary care providers. 12, 16, 17 A number of cost-effectiveness analyses have been published over the past decade with more than half indicating that chemoprevention is a cost-effective option for the prevention of breast cancer among certain groups of high-risk women. These studies simulated a population of women with varied breast cancer risk levels and demographic backgrounds and compared the cost of chemoprevention to the "effectiveness" of the intervention, usually measured as quality-adjusted life years (QALYs). In the analyses evaluated, chemoprevention would be considered cost-effective if the ratio of cost to QALYs saved was below a threshold of $50,000-100,000 and cost-saving if treatment costs were less than placebo or no treatment. The use of chemoprevention drugs was considered "dominated", or always less cost-effective than other options, if treatment was more expensive with less favorable outcomes than an alternative treatment or placebo, or if use of chemoprevention had a negative impact on patient survival. QALYs were generally calculated by multiplying the life years saved by a utility score, representing a subject's preference for a particular outcome, and aggregating these values over the lifetime. Unless otherwise specified, all analyses reviewed in this article used the Gail model to estimate risk for breast cancer in the model population, because this model was used to determine eligibility for the majority of chemoprevention trials conducted in the US. However, the Gail model is not well-validated in certain minority populations (e.g. Hispanics)
and may underestimate breast cancer risk in women with a strong family history of the disease. For the purpose of comparability, we have noted when cost-effectiveness was analyzed for women at a 1.67 % 5-year risk for breast cancer, as this is the definition for high risk used in the chemoprevention trials conducted in the US. 17 While long-term followup trials have not shown an overall survival benefit to chemoprevention, many cost-effectiveness analyses indicate that the treatment may still be cost-effective or cost-saving. Several of these studies have also indicated that the benefits of using chemoprevention outweigh the risks for side effects in these groups. [18] [19] [20] [21] Articles for this review were identified by performing searches through PubMed using several terms, including "breast cancer chemoprevention", "cost-effectiveness of chemoprevention", and "breast cancer costeffectiveness analysis". While selection of papers was not systematic, the literature available in this field is relatively sparse and therefore all cost-effectiveness analyses of chemoprevention drugs for the prevention of breast cancer identified were included. As research over the past 15 years has further clarified the true risk for side effects and the length of time of the protective effect of chemoprevention, we will reassess the findings of these articles in light of new information. 25, 26 Considering this side-effect profile, the population that tends to benefit the most from tamoxifen are high-risk women between 35 to 50 years of age and women who have had a hysterectomy. 17 Since 1998, there have been several studies of the cost-effectiveness of tamoxifen for the prevention of breast cancer, both by itself and in comparison to other pills and prevention strategies.
The first few comprehensive analyses of the cost-effectiveness of tamoxifen were published in the early 2000s. These studies were important in determining which women would benefit most from tamoxifen treatment given the perceived risk for negative side effects and the lack of long-term outcome data available at the time from the BCPT. 19 with a uterus, the tamoxifen price necessary to achieve $100,000 per life year saved, a higher but generally accepted cost threshold, would be $144 per year, while the average health maintenance organization (HMO) price in the US was $415 at the time. The low benefit to women with a 5-year breast cancer risk for 1.67 % was largely due to the risk for side effects; a 3-4 % 5-year risk for breast cancer was the minimum necessary for there to be benefits to tamoxifen therapy. 27 The discrepancy between these findings and previous studies indicated the need to develop a more robust and validated model of the cost-effectiveness of tamoxifen. these values into a model following 50-year-old women with a 1.67 % and 3 % 5-year risk for breast cancer. As with their previous study, the authors found that tamoxifen for chemoprevention was not cost-effective.
Among women with a uterus and a 1.67 % 5-year risk for breast cancer, tamoxifen was shown to have a negative benefit of 9.3 days lost; among women without a uterus, the benefit was only 6.8 days at a cost per QALY of $300,030. In the group with a 3 % 5-year risk, costs per QALY were $167,718 and $68,262 for women with and without a uterus, respectively.
When a "global utility" rating that weighed participants overall preferences towards tamoxifen, instead of a separate utility for each outcome, was incorporated into the analysis, using the pill resulted in a loss of almost an entire year for all groups. While this study reinforced the previous findings by Melnikow et al., it also indicated the need to use highly validated measurements of patient preferences with cost-effectiveness analysis. 
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Selected results from these studies are summarized in Table 1 . While the most recent study indicates that tamoxifen for chemoprevention is cost-effective, the wide range of cost per QALY ratios, from $1,600
to over $1,300,000, to treatment being cost-saving or dominated by placebo, indicate the lack of consensus in the available literature. Costeffectiveness models are highly sensitive to the costs, utilities, and outcomes input by researchers as well as the assumptions that must be made to fully capture all aspects of breast cancer chemoprevention.
As additional data about the long-term outcomes of tamoxifen for chemoprevention, patient utility towards side effects, and costs of breast cancer care become available, it will be necessary for researchers to build new models to effectively guide policy.
Raloxifene
Like tamoxifen, raloxifene is a SERM that was initially investigated for purposes other than breast cancer prevention. Raloxifene has been shown to decrease the risk for fractures and increase bone density and in 1997 the FDA approved raloxifene for the treatment of osteoporosis in postmenopausal women. 6 However, among women at average risk for breast cancer and coronary heart disease, HRT was more cost-effective than raloxifene if taken for 
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OncOlOgy & HematOlOgy Review an entire lifetime assuming, based on available data, that raloxifene did not lead to a sustained reduction in breast cancer rates. In the 5-and 10-year treatment models, raloxifene was more cost-effective than HRT, at a cost per QALY of $43,056 and $3,830 among women with a lifetime breast cancer risk for 15 % and 30 %, respectively. The model was highly sensitive to risk for coronary heart disease and breast cancer risk; if HRT increased the risk for breast cancer or was not as effective at preventing heart disease, raloxifene was usually more cost-effective. The authors noted that their model was limited by the lack of data available on the long-term outcomes of raloxifene for chemoprevention. 21 This paper predates the results of the Women's Health Initiative (WHI) study on HRT, which indicated that HRT actually increased the risk for coronary heart disease in women compared with placebo. 31 Incorporating the results of this analysis would potentially show increased cost-effectiveness for raloxifene if it were performed again. cancer risk, however, increases in QALYs were less steep with age; that is, older women saw benefits from raloxifene use, but at less-steep rates than younger women. While there were still benefits to the women with the lowest rates of fracture and breast cancer risk in sensitivity analysis, the treatment was no longer cost-effective at a cost threshold of $50,000.
However, raloxifene was cost-effective for women at all examined ages with a 5-year breast cancer risk for at least 4 % regardless of fracture risk rate. Similarly, raloxifene was cost-effective or almost cost-effective for all women at a fracture risk rate of 15-19.9 %, regardless of 5-year breast cancer risk. 32 Selected results from these two studies are summarized in Table 1 . As with the analyses of tamoxifen, the cost-effectiveness of raloxifene was highly sensitive to the costs and outcomes selected by researchers. As raloxifene is frequently prescribed for the prevention of fractures, most cost-effectiveness analyses for this intervention do not focus solely on chemoprevention. While the STAR trial compared the outcomes of tamoxifen and raloxifene, there is a lack of available literature on how these two interventions compare under cost-effectiveness analysis.
An analysis of chemoprevention use in Australia found that both treatments were cost-effective among women with a 1.67 % 5-year risk for breast cancer and that raloxifene may be more cost-effective than tamoxifen among high-risk postmenopausal women. 33 Future models incorporating both tamoxifen and raloxifene for chemoprevention would be useful for understanding which treatments are most costeffective for certain populations.
Aromatase Inhibitors
There are currently several classes of AIs under investigation for the prevention of breast cancer, most notably anastrozole and exemestane.
AIs work by blocking the synthesis of estrogen by inhibiting the enzyme aromatase and are only effective in preventing ER-positive breast cancers in postmenopausal women. Like tamoxifen, AIs are also used for the treatment of ER-positive breast cancer. While none are FDA approved for breast cancer prevention, evidence from recent studies suggests that both may decrease breast cancer incidence. 7 The MAP-3 trial demonstrated that exemestane decreased breast cancer risk by up to 65 % among highrisk postmenopausal women. 9 The IBIS-II trial indicated that anastrozole may decrease the risk for breast cancer by up to 53 % in postmenopausal women, aged 40-70 with a 5-year risk for breast cancer higher than the general population. 10 AIs tend to have a different side-effect profile with no increased risk for endometrial cancer or thromboembolic events, although there is evidence of an increased, but not statistically significant, risk for fracture. 9 One study has indicated that use of exemestane for at least 2 years may lead to loss of bone density. 34 The populations that stand to benefit most from AIs for the prevention of breast cancer are postmenopausal women at high-risk for breast cancer with no history of osteoporosis. Thus, while many analyses showed that AIs were more cost-effective than tamoxifen for the treatment of breast cancer, providers should be wary in using these studies to guide policy. 35 While cost-effectiveness analyses can be useful for directing practice, any future studies of the cost-effectiveness of AIs for chemoprevention should attempt to avoid the pitfalls that have been identified in the adjuvant studies.
Conclusions
As healthcare costs increase and the ability to screen women for breast cancer risk improves, it will be critical for providers to be able to compare the cost-effectiveness of different chemoprevention regimens.
The available literature on this topic is relatively sparse. Many of the analyses included in this review are from the early 2000s, before longterm outcome data on chemoprevention and generic versions of these medications were available. For tamoxifen, the risk for severe side effects has led to a wide range of cost-effectiveness estimates among women at high-risk for breast cancer. While the most recent analyses indicate that tamoxifen is cost-effective in women with a 5-year breast cancer risk for 1.67 % or higher, it will be necessary to revisit these studies and compare tamoxifen with other chemoprevention options as more data become available. Similarly, raloxifene has been found to be a cost-effective option for postmenopausal women at high-risk for breast cancer, but all the available cost-effectiveness papers have tended to focus on the use of the drug for fracture risk reduction. There are no papers available on the cost-effectiveness of AIs for breast cancer risk reduction, however, a systematic review has indicated that studies comparing AIs to tamoxifen for adjuvant therapy tend to inadequately address uncertainty. As longterm follow-up data from the chemoprevention trials of AIs emerge, it will be important to compare these options to both of the SERMs.
Costs of cancer care have continued to grow dramatically over the past several years, and it is estimated that this trend will continue. 4 The rise in the cost of breast cancer care is driven both by the high expense of therapy, as well as the length over which treatment needs to occur. 36 Generic versions of tamoxifen, raloxifene, and the AIs are available, and a recent paper by Hershman et al. has established that lower costs of copayments for adjuvant hormonal therapy may increase adherence to treatment. 37 Further research into how decreased costs of chemoprevention medications improve uptake and adherence could potentially have an impact on the overall cost-effectiveness of this preventative therapy.
There is no established association between uptake of chemoprevention and reduction in breast cancer-related deaths, that is, use of tamoxifen or raloxifene for prevention of breast cancer does not reduce fatalities from breast cancer. By preventing breast cancers before they occur, chemoprevention has the potential to reduce costs associated with breast cancer treatment. Establishing whether or not chemoprevention is cost-effective is critical to determining whether preventative treatment for breast cancer results in improved cost and health outcomes for both patients and healthcare systems. ■
